In some cases, such as with smokers harboring BRAF-mutant lung cancer, the presence of such a mutation is associated with longer median progression-free survival (PFS) when compared to non-mutant groups when treated with immune checkpoint inhibitors. Here, BRAF is linked to lung carcinoma.